Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer
- PMID: 20800390
- DOI: 10.1016/j.ijrobp.2010.05.043
Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer
Abstract
Purpose: To compare the nodal risk formula (NRF) as a predictor for lymph node (LN) metastasis in patients with prostate cancer with magnetic resonance lymphography (MRL) using Ultrasmall Super-Paramagnetic particles of Iron Oxide (USPIO) and with histology as gold standard.
Methods and materials: Logistic regression analysis was performed with the results of histopathological evaluation of the LN as dependent variable and the nodal risk according to the NRF and the result of MRL as independent input variables. Receiver operating characteristic (ROC) analysis was performed to assess the performance of the models.
Results: The analysis included 375 patients. In the single-predictor regression models, the NRF and MRL results were both significantly (p<0.001) predictive of the presence of LN metastasis. In the models with both predictors included, NRF was nonsignificant (p=0.126), but MRL remained significant (p<0.001). For NRF, sensitivity was 0.79 and specificity was 0.38; for MRL, sensitivity was 0.82 and specificity was 0.93. After a negative MRL result, the probability of LN metastasis is 4% regardless of the NRF result. After a positive MRL, the probability of having LN metastasis is 68%.
Conclusions: MRL is a better predictor of the presence of LN metastasis than NRF. Using only the NRF can lead to a significant overtreatment on the pelvic LN by radiation therapy. When the MRL result is available, the NRF is no longer of added value.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.Curr Urol Rep. 2014 Mar;15(3):389. doi: 10.1007/s11934-013-0389-7. Curr Urol Rep. 2014. PMID: 24430170 Review.
-
Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram.Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1186-91. doi: 10.1016/j.ijrobp.2012.02.039. Epub 2012 Apr 18. Int J Radiat Oncol Biol Phys. 2012. PMID: 22520482
-
Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):712-8. doi: 10.1016/j.ijrobp.2011.12.093. Epub 2012 Mar 13. Int J Radiat Oncol Biol Phys. 2012. PMID: 22417806
-
Magnetic resonance lymphography: a novel technique for lymph node assessment in gynecologic malignancies.Cancer Biomark. 2009;5(2):81-8. doi: 10.3233/CBM-2009-0543. Cancer Biomark. 2009. PMID: 19414925 Review.
-
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.Lancet Oncol. 2008 Sep;9(9):850-6. doi: 10.1016/S1470-2045(08)70203-1. Epub 2008 Aug 15. Lancet Oncol. 2008. PMID: 18708295 Clinical Trial.
Cited by
-
Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.Curr Urol Rep. 2014 Mar;15(3):389. doi: 10.1007/s11934-013-0389-7. Curr Urol Rep. 2014. PMID: 24430170 Review.
-
Individualized image-based lymph node irradiation for prostate cancer.Nat Rev Urol. 2013 Jul;10(7):376-85. doi: 10.1038/nrurol.2013.111. Epub 2013 May 28. Nat Rev Urol. 2013. PMID: 23712209 Review.
-
Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?J Natl Cancer Inst Monogr. 2012 Dec;2012(45):221-9. doi: 10.1093/jncimonographs/lgs039. J Natl Cancer Inst Monogr. 2012. PMID: 23271777 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical